A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

October 14, 2027

Study Completion Date

October 14, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986484

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Oxaliplatin

Specified dose on specified days

DRUG

Capecitabine

Specified dose on specified days

DRUG

Fluorouracil

Specified dose on specified days

DRUG

Calcium folinate

Specified dose on specified days

Trial Locations (11)

2010

RECRUITING

St Vincent's Hospital, Darlinghurst

5112

RECRUITING

Lyell McEwin Hospital, Elizabeth Vale

49546

RECRUITING

START Midwest, Grand Rapids

57104

RECRUITING

Sanford Cancer Center, Sioux Falls

78229

RECRUITING

NEXT Oncology, San Antonio

85719

RECRUITING

University of Arizona Cancer Center, Tucson

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H2X 0A9

RECRUITING

Centre Hospitalier de l'Université de Montréal, Montreal

104-0045

NOT_YET_RECRUITING

Local Institution - 0023, Chuo-ku

277-8577

NOT_YET_RECRUITING

Local Institution - 0022, Kashiwa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY